# Lakefront Biotherapeutics NV share price today (Lakefront Biotherapeutics NV, LKFT)

> Lakefront Biotherapeutics NV's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. LKFT · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/lkft

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $33.56 (+6.4% in a year)
- P/E: 3.3×, over 4.1 years
- Revenue (Jun 2026): $12.1 M (−81.5% on a year ago)
- Profit (Jun 2026): $2.1 M
- Operating margin: −359.3% (−385.8 points on a year ago)
- ROE: 10%, FY25

The main question: yearly earnings per share moved +333.7% while the share price moved +6.4%. ## What is the Lakefront Biotherapeutics NV share price today? Lakefront Biotherapeutics NV's share price was $33.56 at the close on 5 November 2026. It has been stalling near its high for 3 weeks. That is 12.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between $27 and $34, and at that close it sat 89% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. Over the last 10 years the share price moved −39% while the S&P 500 moved +245%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Lakefront Biotherapeutics NV pay? Lakefront Biotherapeutics NV pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Lakefront Biotherapeutics NV on? Lakefront Biotherapeutics NV is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Lakefront Biotherapeutics NV profitable? Lakefront Biotherapeutics NV earned $2.1 M of net profit in the Jun 2026 quarter. Full-year FY25 profit was $321 M. That is 17.4% of the quarter's revenue. The same quarter a year earlier lost $106 M. 4 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $321 M (+333.1% on the year before). ## How much revenue does Lakefront Biotherapeutics NV make, and is it growing? Lakefront Biotherapeutics NV reported $12.1 M of revenue in the Jun 2026 quarter, −81.5% on the same quarter a year earlier. Over 4 years it has grown 47.6% a year on average. The last full year, FY25, came in at $1.1 B. The last four reported quarters add to $991 M. FY25 revenue was $1.1 B, +303.5% on the year before. Recent pace: the last four quarters grew −51.3% on average, against 47.6% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +256.3%, against +81.4% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Lakefront Biotherapeutics NV keep? Lakefront Biotherapeutics NV's operating margin was −359.3% in the Jun 2026 quarter, 385.8 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −73.2% and 48.1%. The latest quarter is below every full year in that period. Across 5 years it has been between −73.2% and 48.1%, and FY25's 48.1% is the highest of them. Why the margin moved: operating margin changed −385.8 percentage points on the year while gross margin changed −221.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Lakefront Biotherapeutics NV's profit turning into cash? Over the last 3 years Lakefront Biotherapeutics NV's operations used more cash than they brought in, so cash conversion was −162%, a gap worth watching. In FY25 its operations used $257 M of cash, against $321 M of profit. After $13.7 M of spending on assets, free cash was −$271 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Lakefront Biotherapeutics NV's cash go? Lakefront Biotherapeutics NV does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $49.1 M on assets over the last 3 years. Averaged over those years that is 1.5% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $49.1 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Lakefront Biotherapeutics NV's P/E ratio, and how does it compare with its own history? Lakefront Biotherapeutics NV's P/E is 3.3×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +333.7% while the price moved +6.4%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved −3.3% a year; about +99.2% a year came from earnings growth and about −102.5 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Lakefront Biotherapeutics NV business getting better or worse? Lakefront Biotherapeutics NV's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 11 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Lakefront Biotherapeutics NV earn on its capital? Lakefront Biotherapeutics NV earned a ROE of 10% in FY25. That is up from a low of −9% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads 2,989%, a number that says nothing useful about the business. It comes from a 28.9% net margin and 0.33× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 28.9% net margin × 0.33× asset turnover × 1.05× leverage (assets divided by equity) ≈ 10.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. ## Does Lakefront Biotherapeutics NV have too much debt? Lakefront Biotherapeutics NV has total debt of $6.4 M against shareholder equity of $3.3 B as of Jun 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.00 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Lakefront Biotherapeutics NV shareholding pattern? We have no ownership or short-position figures for Lakefront Biotherapeutics NV, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 4.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Lakefront Biotherapeutics NV from balance-sheet trouble? For Lakefront Biotherapeutics NV, the Z-score is 13.92. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 13.92 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Lakefront Biotherapeutics NV rank in its industry? There is no score against its industry: Lakefront Biotherapeutics NV is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Lakefront Biotherapeutics NV compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Lakefront Biotherapeutics NV in size? Lakefront Biotherapeutics NV is the 73rd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Septerna, Inc., Recursion Pharmaceuticals, Inc. and Aurinia Pharmaceuticals Inc. Just below it: Immunome, Inc., Zymeworks Inc. and Fortrea Holdings Inc. ### Biotechnology companies close in size

1. [Septerna, Inc.](https://www.sectoralpha.in/us/stocks/sepn) $2.2 billion
2. [Recursion Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/rxrx) $2.2 billion
3. [Aurinia Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/auph) $2.2 billion
4. Lakefront Biotherapeutics NV $2.2 billion
5. [Immunome, Inc.](https://www.sectoralpha.in/us/stocks/imnm) $2.1 billion
6. [Zymeworks Inc.](https://www.sectoralpha.in/us/stocks/zyme) $2 billion
7. [Fortrea Holdings Inc.](https://www.sectoralpha.in/us/stocks/ftre) $2 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Liberty Energy Inc.](https://www.sectoralpha.in/us/stocks/lbrt) $2.1 billion · Oil & Gas Equipment & Services
2. [Hilltop Holdings Inc.](https://www.sectoralpha.in/us/stocks/hth) $2.1 billion · Financial Conglomerates
3. Lakefront Biotherapeutics NV $2.1 billion
4. [Schrödinger, Inc.](https://www.sectoralpha.in/us/stocks/sdgr) $2.1 billion · Health Information Services
5. [DENTSPLY SIRONA Inc.](https://www.sectoralpha.in/us/stocks/xray) $2.1 billion · Medical Instruments & Supplies

## What else do people ask about Lakefront Biotherapeutics NV? ### What were Lakefront Biotherapeutics NV's latest quarterly results? Lakefront Biotherapeutics NV reported revenue of $12.1 M and net profit of $2.1 M for the Jun 2026 quarter. Earnings per share were $0.03. The operating margin was −359.3%, 385.8 percentage points lower than a year earlier (as of 5 November 2026). ### What is Lakefront Biotherapeutics NV's market cap? Lakefront Biotherapeutics NV's market capitalisation is $2.2 B at a stock price of $33.56. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Lakefront Biotherapeutics NV performing? Lakefront Biotherapeutics NV's share price has been stalling near its high for 3 weeks. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Lakefront Biotherapeutics NV's stock price go up? This page does not forecast Lakefront Biotherapeutics NV's stock price. What it shows instead: the stock price is $33.56, and it has been stalling near its high for 3 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is Lakefront Biotherapeutics NV in its business cycle? Lakefront Biotherapeutics NV's FY25 operating margin was 48.1%, against a 5-year range of −73.2% to 48.1%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was −359.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Lakefront Biotherapeutics NV story? The main question: yearly earnings per share moved +333.7% while the share price moved +6.4%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Lakefront Biotherapeutics NV a stock worth studying right now? What the numbers show: Lakefront Biotherapeutics NV's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.